1. Introduction {#sec1-molecules-21-00706}
===============

Salidroside (*p*-hydroxyphenethyl-beta-[d]{.smallcaps}-glucoside), a compound with a chemical structure of phenol glycosides ([Figure 1](#molecules-21-00706-f001){ref-type="fig"}), has been identified as one of the most potent ingredients isolated from *Rhodiola crenulata* \[[@B1-molecules-21-00706]\]. Salidroside reportedly possesses broad pharmacological activities, such as resisting anoxia \[[@B2-molecules-21-00706]\], anti-fatigue \[[@B3-molecules-21-00706]\], anti-inflammation \[[@B4-molecules-21-00706],[@B5-molecules-21-00706]\], anti-aging \[[@B6-molecules-21-00706]\], anti-cancer \[[@B7-molecules-21-00706],[@B8-molecules-21-00706],[@B9-molecules-21-00706]\], antioxidation \[[@B10-molecules-21-00706]\], cardioprotective \[[@B11-molecules-21-00706]\], and hepatoprotective \[[@B12-molecules-21-00706]\] properties. As a well-known natural product, salidroside is widely used as a bioactive ingredient for functional foods, dietary supplements, and phytomedicines around the world \[[@B13-molecules-21-00706],[@B14-molecules-21-00706],[@B15-molecules-21-00706],[@B16-molecules-21-00706]\].

Although salidroside exhibited a wide variety of biological activities in *in vitro* and *in vivo* experiments, only a few reports regarding the metabolism and disposition of salidroside are available. Han *et al.* developed a LC/MS method to identify salidroside and its major metabolites in rat plasma, bile, urine and feces, and up to 7 metabolites were detected. Among them, sulfate and glucuronidation conjugation were the primary pathway for salidroside \[[@B17-molecules-21-00706]\]. Hu *et al.* identified eight metabolites of salidroside from the rat urine samples via ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry and high performance liquid chromatography coupled with quadrupole-linear ion trap mass spectrometry \[[@B18-molecules-21-00706]\]. Guo *et al.* studied the metabolism of salidroside to its aglycone *p*-Tyrosol in rats \[[@B19-molecules-21-00706]\]. However, the existing results could not provide a comprehensive map of the dynamic biotransformation process of salidroside following oral administration. Accordingly, it is necessary to study the sequential metabolic changes of salidroside *in vivo.*

Hence, the primary goal of this study was to develop a holistic, sequential and reproducible approach to describe the complicated sequential metabolism of salidroside before absorption into the systemic blood stream. In brief, the approach includes four fundamental steps: (1) enzymatic transformation in digestive juice, (2) biotransformation by intestinal flora tract, (3) gut wall metabolism, and (4) hepatic metabolism \[[@B20-molecules-21-00706]\]. The approach was based on comparative analysis and a carefully designed mix of metabolic techniques such as *in vitro* incubation, *in situ* closed-loop and *in vivo* blood sampling. Ultra-high-pressure liquid chromatography coupled with linear ion trap-Orbitrap tandem mass spectrometry (UHPLC-LTQ-Orbitrap) was used to analyze the metabolites of salidroside in different metabolic sites. High-resolution mass spectrometry such as LTQ-Orbitrap plays a crucial role in metabolic analyses owing to its accurate MS data and reliable metabolite identification when attempting to discriminate metabolites with different MS/MS fragments \[[@B21-molecules-21-00706]\]. By the results, we can determine the probable metabolic pathways of salidroside and the sequential contribution of each metabolic site. Research on the sequential metabolism of salidroside would provide helpful information on how the biological activities of these components are changed before these components are delivered to the target sites.

2. Results and Discussion {#sec2-molecules-21-00706}
=========================

2.1. Stability of Salidroside in Artificial Gastric Juice and Intestinal Juice {#sec2dot1-molecules-21-00706}
------------------------------------------------------------------------------

Salidroside was quite stable in artificial gastric juice and intestinal juice. The content of salidroside was not altered significantly according to the peak areas during *in vitro* incubation with digestive juices (RSD \< 5.0%).

2.2. Fragmentation of Salidroside Standard {#sec2dot2-molecules-21-00706}
------------------------------------------

The chromatographic and mass spectrometric conditions were optimized using salidroside standard. Metabolite characterization was on the basis of the fragmentation patterns of salidroside.

As shown in [Figure 2](#molecules-21-00706-f002){ref-type="fig"}A, the deprotonated molecular ion of salidroside at *m*/*z* 299.1126 gave rise to six major product ions at *m*/*z* 113.0242, 119.0348, 131.0346, 143.0347, 161.0451, 179.0556. Two important fragmentations from deprotonated salidroside were the cleavage of the glycosidic linkage leading to the formation of *m*/*z* 179.0556 and 119.0348. The fragment at *m*/*z* 161.0451 was generated through the loss of H~2~O from the ion at *m*/*z* 179.0556, and then produced the ion at *m*/*z* 143.0347 by the further elimination of H~2~O. The fragment ion at *m*/*z* 131.0346 was rationalized to originate from the product ion at *m*/*z* 179.0556 through the loss of one molecule of CH~2~O and one molecule of H~2~O. Subsequently, the predominant fragmentation ion at *m*/*z* 113.0242 was produced by the reduction of H~2~O from *m*/*z* 131.0346. Thus, it can be concluded that the ions at *m*/*z* 113.0242, 119.0347, 131.0346, 143.0347, 161.0451, 179.0556 were the characteristic product ions of salidroside.

2.3. Identification of Salidroside Metabolites in Different Plasma Samples {#sec2dot3-molecules-21-00706}
--------------------------------------------------------------------------

Metabolites of salidroside were detected and identified by comparing plasma samples from salidroside-treated rats with corresponding control samples. The structures of the metabolites were elucidated by comparing their molecular weights and product ions with those of the parent drug \[[@B22-molecules-21-00706]\]. A total of 4 metabolites were found from different plasma samples. Detailed information on salidroside (M0) and its metabolites (M1--M4) was summarized in [Table 1](#molecules-21-00706-t001){ref-type="table"}.

### 2.3.1. Parent Compound M0 {#sec2dot3dot1-molecules-21-00706}

Salidroside (M0) was identified according to the UHPLC retention time (11.17 min), the accurate MS at *m*/*z* 299.1126 \[M − H\]^−^, and MS/MS spectra from the authentic standard. Characteristic fragment ions at *m*/*z* 113, 119, 131, 143, 161, 179 could also be found in the MS/MS spectra.

### 2.3.2. Metabolite M1 {#sec2dot3dot2-molecules-21-00706}

M1 (retention time t~R~ = 8.32 min) showed the molecular ion at *m*/*z* 313.0932 (4.5 ppm, elemental composition of C~14~H~17~O~8~), which was 176 Da higher than the *m*/*z* of the aglycone *p*-tyrosol, suggesting a glucuronic acid group was conjugated to the aglycone *p*-tyrosol \[[@B18-molecules-21-00706]\]. According to the MS/MS spectrum ([Figure 2](#molecules-21-00706-f002){ref-type="fig"}B), two major product ions of M1 were found at *m*/*z* 175.0254 (the \[M − H\]^−^ ion of glucuronic acid) and 113.0249 (C~5~H~5~O~3~). The fragment at *m*/*z* 295.0826 was generated through the loss of H~2~O from the quasi-molecular ion.

### 2.3.3. Metabolite M2 {#sec2dot3dot3-molecules-21-00706}

M2 (retention time t~R~ = 8.93 min) displayed an \[M − H\]^−^ ion at *m*/*z* 475.1464 (3.8 ppm, elemental composition of C~20~H~27~O~13~), which was 176 Da higher than the *m*/*z* of M0, indicating that it was the glucuronide conjugated product of salidroside \[[@B18-molecules-21-00706]\]. The major fragment ion ([Figure 2](#molecules-21-00706-f002){ref-type="fig"}C) at *m*/*z* 457.1329 was a H~2~O loss from the quasi-molecular ion. The product ions at *m*/*z* 175.0242 and 299.1121 were ions of glucuronic acid and salidroside produced by M2.

### 2.3.4. Metabolite M3 {#sec2dot3dot4-molecules-21-00706}

M3 (retention time t~R~ = 10.80 min) exhibited a \[M − H\]^−^ ion at *m*/*z* 379.0691 (−0.6 ppm, elemental composition of C~14~H~19~O~10~S), which was 80 Da heavier than that of salidroside, indicating sulfation of salidroside \[[@B18-molecules-21-00706]\]. The major fragment ion determined at *m*/*z* 217.0170 was shaped by the elimination of Glu (162 Da). Characteristic product ions at *m*/*z* 299, 137, 119 were also found in the MS^2^ fragmentation ([Figure 2](#molecules-21-00706-f002){ref-type="fig"}D).

### 2.3.5. Metabolite M4 {#sec2dot3dot5-molecules-21-00706}

M4 (retention time t~R~ = 11.61 min) exhibited a \[M − H\]^−^ ion at *m*/*z* 217.0173 (3.4 ppm, elemental composition of C~8~H~9~O~5~S), which was 80 Da heavier than that of the aglycone *p*-tyrosol, indicating a sulfuric acid group was M4 \[[@B18-molecules-21-00706]\]. The major fragment ion ([Figure 2](#molecules-21-00706-f002){ref-type="fig"}E) at *m*/*z* 137.0610 was the aglycone *p*-tyrosol.

2.4. The Sequential Process of Salidroside in the Digestive System {#sec2dot4-molecules-21-00706}
------------------------------------------------------------------

Using the sequential metabolism method, a total of 4 metabolites of salidroside have been detected and identified in different plasma samples. Our results indicated that glucuronidation, sulfation, and deglycosylation were the major metabolic pathways of salidroside. The contribution of each metabolic site to the overall metabolism was also shown in [Table 1](#molecules-21-00706-t001){ref-type="table"}. When salidroside was administered orally, enzymes in the gut wall may play an important role in the initial metabolism. However, results showed that the biotransformation rate of salidroside by the gut wall was very low. It can be noted that intestinal flora tract and liver were the major metabolic sites for salidroside. Salidroside appears to undergo sequential and multiple pathways of degradation and metabolism by intestinal flora tract and liver to produce active metabolites or intermediates, thereby exerting *in vivo* pharmacological functions. The sequential process of salidroside in the digestive system is shown in [Figure 3](#molecules-21-00706-f003){ref-type="fig"}.

3. Experimental Section {#sec3-molecules-21-00706}
=======================

3.1. Chemicals and Reagents {#sec3dot1-molecules-21-00706}
---------------------------

Salidroside (purity \> 98%) was purchased from Nanjing Zelang Biological Technology Co., Ltd. (Jiangsu, China). HPLC-grade acetonitrile and formic acid were obtained from Fisher Scientific. High purity water was prepared by using the Millipore Milli Q plus purification system. All other solvents and chemicals used were of analytical grade and commercially available.

The perfusion solution was Krebs--Ringer (K--R) buffer solution, which contained 7.8 g NaCl, 0.35 g KCl, 1.37 g NaHCO~3~, 0.02 g MgCl~2~, 0.32 g NaH~2~PO~4~, and 1.48 g glucose in 1000 mL distilled water.

3.2. Preparation Perfusion Solution of Salidroside {#sec3dot2-molecules-21-00706}
--------------------------------------------------

The perfusion solution of 10 mg/mL salidroside was prepared by dissolving 500 mg salidroside in 50 mL K--R buffer solution.

3.3. Animals {#sec3dot3-molecules-21-00706}
------------

Sprague-Dawley rats (male, 200--250 g) were obtained from Spfanimals Laboratory Animal Technology Co. Ltd (Beijing, China). All animal experiments were conducted using protocols approved by the University Committee on Ethics in the Care and Use of Laboratory Animals (SYXKJING(2001-0024)), and the animals were housed and handled according to the Laboratory Animal Medicine Guidelines of Beijing University of Chinese Medicine. Before the study, the rats were kept in a temperature- and humidity-controlled room (23 °C, 60% air humidity) with unlimited access to standard diet and water. The rats were acclimated for at least 7 days, then fasted overnight but supplied with water *ad libitum* prior to the date of the experiment.

3.4. Stability in Digestive Juice with Enzymes {#sec3dot4-molecules-21-00706}
----------------------------------------------

Salidroside (1 mg) was added into 15 mL of artificial gastric juice (0.08 M HCl containing 50 mg of pepsin, pH 1.5) and incubated in a 37 °C shaking water bath for 0.5, 2, or 4 h, respectively. The reactions were rapidly terminated by water-saturated *n*-butanol. The mixture was centrifuged at 5000× *g* for 15 min, and then the supernatant was evaporated to dryness under a stream of nitrogen. The residue was dissolved in 500 μL of methanol, and then filtered through a 0.45 μm membrane for HPLC analysis.

Salidroside (1 mg) was added into 15 mL of artificial intestinal juice (0.05 M KH~2~PO~4~ containing 50 mg of pancreatin, pH 6.8) and incubated in a 37 °C shaking water bath for 1, 3, or 6 h, respectively. The samples were prepared as the procedure described in artificial gastric juice.

3.5. Intestinal Flora Metabolism Method {#sec3dot5-molecules-21-00706}
---------------------------------------

The *in situ* closed-loop method was extensively used to study intestinal absorption. The approach enables intestinal absorption to occur at body temperature for an appointed time. The model also allows absorption to be measured separately at different regions of rat intestine, jejunum, ileum and colon \[[@B23-molecules-21-00706]\].

The complex surgical procedure and the *in situ* closed-loop experiments were conducted in accordance with the methods described previously \[[@B20-molecules-21-00706],[@B23-molecules-21-00706]\]. The rats were divided into two groups. In one group, blood was collected from the mesenteric vein and the drug was injected into the gut loop directly. In the other group, blood was also collected from the mesenteric vein, but the drug was injected only after the intestinal flora had been flushed out.

Before perfusion surgical operation, five to seven rats were selected for donor blood per experiment and a total of 50--70 mL blood was obtained from the abdominal aorta with a heparinized syringe. The blood incubated in a 37 °C water bath was prepared to be transfused into the recipient rat through the jugular vein to balance the blood loss via the mesenteric vein. The recipient rat was anesthetized with chloral hydrate (400 mg/kg) and placed under a heat lamp to maintain normal body temperature. To sustain the anesthetic condition, one third of the initial dose of chloral hydrate was administered in the following experiment.

Upon verification of the loss of pain reflex, the left external jugular vein was exposed and cannulated with a 24 GBD Intima II catheter (Becton Dickinson Medical Devices Co. Ltd, Beijing, China) to transfuse blood collected previously from donor rats. Then the abdomen was opened with a midline incision and a 5 cm colon segment was isolated by two ligatures to form a loop. To collect venous outflow, a 24 G catheter with heparinized saline was inserted into the mesenteric vein draining the segment. The blood flow amounted to 0.3 mL/min to avoid blood loss.

For the study without intestinal flora, the intestinal content was washed out by perfusing the loop with prewarmed K--R buffer solution. When the flora was carefully expelled, air was pumped through the syringe to clean the lumen. Salidroside solution (2 mL) was injected into a loop with a syringe. At the conclusion of surgery, the loop of gut with blood supply intact was covered with Parafilm to reduce evaporation.

For the study with intestinal flora, the operation was the same as described above for the study without intestinal flora except for the flush process.

Mesenteric blood was collected in heparinized centrifuge tubes within 1.5 h. The blood samples were centrifuged at 5000 rpm for 15 min to obtain the plasma, and then treated with 3 volumes of methanol to precipitate protein. The mixture was vortexed for 10 min, and centrifuged at 10,000 rpm for 15 min. The organic layer was transferred to another tube, and evaporated to dryness under a stream of nitrogen at 40 °C. Then, the dried residue was dissolved in 200 μL of methanol for LC/MS analysis.

3.6. Gut Wall Metabolism Method {#sec3dot6-molecules-21-00706}
-------------------------------

About 10 cm of jejunum was selected and the surgical approach for metabolism without intestinal flora was used. Blood samples were collected and prepared as described above.

3.7. Hepatic Metabolism Method {#sec3dot7-molecules-21-00706}
------------------------------

The surgical approach was the same as described above but without blood supplementation and collection. Intestinal flora metabolism and gut wall metabolism would all occur before the hepatic metabolism, and thus 5 cm colon and 10 cm jejunum were used in this experiment. Blood samples were collected from the abdominal aorta after 1.5 h and prepared as described above.

3.8. HPLC Analysis {#sec3dot8-molecules-21-00706}
------------------

The HPLC system used to analyze the stability of salidroside in digestive juice was composed of a Waters 600 controller and pump and a Waters 2487 detector measuring absorbance at 214 nm (Waters Corporation, Milford, MA, USA). The chromatographic separation of salidroside was carried out on a 250 mm × 4.6 mm C~18~ column with acetonitrile/water 80:20 (*v*/*v*) as isocratic mobile phase at 1.0 mL/min. The column temperature was set at 35 °C and the volume injected amounted to 20 μL.

3.9. LC/MS Analysis {#sec3dot9-molecules-21-00706}
-------------------

Sample analyses were performed using an ultimate 3000 LC system coupled to an LTQ Orbitrapmass spectrometer via an ESI interface. The chromatography system consisted of an autosampler, a diode array detector, a column compartment and two pumps. Xcalibur, Metworks and Mass Frontier 7.0 software packages (Thermo Corporation, Waltham, MA, USA) were employed for data collection and data analysis.

Chromatographic separations were performed on a Thermo Scientific BOS Hypersil C~18~ column 2.1 × 150 mm^2^, with 2.4 μm particle size. The mobile phases A and B comprised 0.1% formic acid in water and acetonitrile, respectively. The LC gradient program (time (in min)/%mobile phase B) was set as 0.01/1, 3/1, 6/5, 12/10, 19/50, 24/85, 26/1, 30/1. The chromatographic runs were performed at a flow rate of 0.3 mL/min. The injection volume was 3 μL with column oven at 35 °C.

The ESI source parameters were as follows: the capillary temperature was 250 °C, source voltage and ispray voltage were set at 5 kV, shealth gas (N~2~) flow was 35 psi. The ESI source was operated in the negative ionization mode. In the Fourier transform (FT) cell, full MS scans were acquired in the range of *m*/*z* 50--1000. The MS/MS experiments were set as data-dependent scans.

4. Conclusions {#sec4-molecules-21-00706}
==============

In this paper, a practical approach was established to study the sequential metabolism of salidroside after oral administration. Four metabolites were found in this sequential process and their structures were elucidated according to the retention times, accurate molecular mass, and characteristic fragment ions. The metabolic pathways were proposed and the relative contribution of each metabolic site to the total metabolism of the parent was also determined. Based on the result, the sequential process of salidroside after oral administration was clearly characterized. It was found that most salidroside was converted to the glucuronide and sulfate forms of both the parent compound and the aglycone, and then transported to the target tissues through the blood stream. The results obtained in this study could provide useful information about salidroside bioactivity and beneficial health effects. Furthermore, the proposed sequential metabolism methodology could be applicable to mechanistic studies of other compounds involving complicated sequential metabolic reactions.

This work was supported by the National Natural Science Foundation of China (30801510 and 81274042).

**Sample Availability:** Not available.

Yang Liu conceived and designed the experiments; Zhiqiang Luo, Xiaoyun Ma, Lina Lu, Guohua Yu and Ruirui Yang performed the experiments; Zhiqiang Luo, Xiaoyun Ma and Mohan Sun analyzed the data; Shaokun Xin, Simin Tian, Xinjing Chen and Haiyu Zhao contributed reagents/materials/analysis tools; Zhiqiang Luo wrote the paper.

The authors declare no conflict of interest.

![Chemical structure of salidroside.](molecules-21-00706-g001){#molecules-21-00706-f001}

![Representative MS/MS spectrum: (**A**) M0 (*m*/*z* 299); (**B**) M1 (*m*/*z* 313); (**C**) M2 (*m*/*z* 475); (**D**) M3 (*m*/*z* 379); (**E**) M4 (*m*/*z* 217).](molecules-21-00706-g002){#molecules-21-00706-f002}

![The sequential process of salidroside in the digestive system.](molecules-21-00706-g003){#molecules-21-00706-f003}

molecules-21-00706-t001_Table 1

###### 

UHPLC-LTQ-Orbitrap analysis and relative percentage area of salidroside and four metabolites in different blood samples.

  Metabolite   t~R~/min   Found (Da)   Calculated (Da)   Error (ppm)   Fragment ion *m*/*z* (Da)   Formula            Metabolite Description              Relative Percentage Area in Different Blood Samples ^1^                     
  ------------ ---------- ------------ ----------------- ------------- --------------------------- ------------------ ----------------------------------- --------------------------------------------------------- -------- -------- --------
  M0           11.17      299.1126     299.1125          0.4           179.0556                    C~14~H~20~O~7~     Parent                              94.26%                                                    99.59%   43.85%   22.93%
  119.0348                                                                                                                                                                                                                            
  161.0451                                                                                                                                                                                                                            
  143.0347                                                                                                                                                                                                                            
  131.0346                                                                                                                                                                                                                            
  113.0242                                                                                                                                                                                                                            
  M1           8.32       313.0932     313.0918          4.5           175.0254                    C~14~H~18~O~8~     Deglycosylation + Glucuronidation   2.17%                                                     0.38%    15.67%   7.43%
  113.0249                                                                                                                                                                                                                            
  295.0826                                                                                                                                                                                                                            
  M2           8.93       475.1464     475.1446          3.8           457.1329                    C~20~H~28~O~13~    Glucuronidation                     0.66%                                                     0.04%    3.52%    16.42%
  175.0242                                                                                                                                                                                                                            
  299.1121                                                                                                                                                                                                                            
  M3           10.80      379.0691     379.0693          −0.6          217.0170                    C~14~H~20~O~10~S   Sulfation                           2.91%                                                     ND       7.00%    11.00%
  299.1123                                                                                                                                                                                                                            
  137.0605                                                                                                                                                                                                                            
  119.0500                                                                                                                                                                                                                            
  M4           11.61      217.0173     217.0165          3.4           137.0610                    C~8~H~9~O~5~S      Deglycosylation + Sulfation         ND ^3^                                                    ND       29.96%   42.23%

^1^ The relative percentage area was calculated as (peak area of each metabolite/total peak area of metabolites) × 100%; ^2^ GWM, gut wall metabolism; WOIF, without intestinal flora group; WIIF, within intestinal flora group; HM, hepatic metabolism; ^3^ Not detected.

[^1]: These authors contributed equally to this work.
